Compounds > bms-605339
Page last updated: 2024-11-13

bms-605339

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID46862685
CHEMBL ID2403888
SCHEMBL ID12054434
MeSH IDM0587203

Synonyms (13)

Synonym
2R8 ,
n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-n-{(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-4-[(6-methoxyisoquinolin-1-yl)oxy]-l-prolinamide
CHEMBL2403888 ,
tert-butyl n-[(1s)-1-[(2s,4r)-2-[[(1r,2s)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]-4-[(6-methoxy-1-isoquinolyl)oxy]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate
SCHEMBL12054434
cyclopropanecarboxamide, n-((1,1-dimethylethoxy)carbonyl)-3-methyl-l-valyl-(4r)-4-((6-methoxy-1-isoquinolinyl)oxy)-l-prolyl-1-amino-n-(cyclopropylsulfonyl)-2-ethenyl-, (1r,2s)-
x5cv3yw4gq ,
unii-x5cv3yw4gq
630417-82-2
4NWK
bms-605339
Q27453206
bdbm50461550

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The overall preclinical pharmacokinetic profile supported the selection and development of BMS-605339 as a clinical candidate."( Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor.
Arora, V; Gesenberg, C; Jenkins, S; Knipe, J; McPhee, F; Pilcher, G; Santone, K; Scola, P; Sinz, M, 2014)		0.87

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of BMS-605339 was variable and dose dependent, suggesting low absorption, possibly because of transporter involvement."( Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor.
Arora, V; Gesenberg, C; Jenkins, S; Knipe, J; McPhee, F; Pilcher, G; Santone, K; Scola, P; Sinz, M, 2014)		0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein IC50 (µMol)0.09470.00000.02890.1870AID1392001; AID1392004; AID1392005
Non-structural protein 4A IC50 (µMol)0.09470.00000.02890.1870AID1392001; AID1392004; AID1392005
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)2.00000.00011.753610.0000AID1076370
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (83)

Assay IDTitleYearJournalArticle
AID1076366Antiviral activity against Hepatitis C virus genotype 1 infected in human assessed as reduction in plasma viral load administered orally measured after 12 hrs2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID759183Half life in human liver microsomes2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
AID1076408Inhibition of Hepatitis C virus genotype 1a H77 recombinant NS3/4A protease expressed in Escherichia coli BL21 (DE3) cell using Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu[C(O)-O]-Ala-Ser-Lys(DABCYL)-NH2 as substrate by FRET assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076383Antiviral activity against Bovine viral diarrhea virus2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076403Apparent terminal half life in Sprague-Dawley rat at 5 mg/kg, iv by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1392000Antiviral activity against HCV infected in human patient assessed as reduction in viral load at 120 mg administered as single dose2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1434264Half life in rat at 5 mg/kg, iv2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076375Ratio of drug level in liver to plasma in Beagle dog at 14 mg/kg, po measured after 24 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076362Cardiovascular toxicity in healthy human assessed as junctional rhythm disturbances at 120 mg, po by electrocardiography2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1323423Cardiotoxicity in rabbit heart assessed as change in heart rate at 10 uM perfused for 20 mins measured for 1 min by electrophysiology method relative to control2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1392003Aqueous solubility in pH 6.5 phosphate buffer2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID759173Solubility of the compound at pH 62013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
AID1434258Permeability of the compound at pH 7.4 by PAMPA2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1392005Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1076407Antiviral activity against Hepatitis C virus genotype 1b Con1 after 4 days by cell-based replicon assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076368Tmax in po dosed human2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1323415Clearance in cannulated Sprague-Dawley rat plasma at 5 mg/kg, iv administered as 10 mins infusion measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1434265Drug uptake in rat liver at 15 mg/kg, po after 24 hrs2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID759184Half life in rat liver microsomes2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
AID1076361Cardiovascular toxicity in Hepatitis C virus genotype 1 infected human assessed as mild bradycardia at 120 mg, po by electrocardiography2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076392AUC in intraduodenally dosed Sprague-Dawley rat plasma measured over 4 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434255Inhibition of HCV genotype 1a NS3/4A protease2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076376Ratio of drug level in liver to plasma in Sprague-Dawley rat at 15 mg/kg, po administered via gavage measured after 24 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076404Whole body plasma clearance in Sprague-Dawley rat at 5 mg/kg, iv by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1392001Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID759186Permeability across apical to basolateral side in human Caco2 cells2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
AID1076390AUC in Sprague-Dawley rat at 15 mg/kg, po administered via gavage by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076372Drug uptake into human hepatocytes by silicone oil layer method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434267Cardiotoxicity in Langendorff perfused rabbit heart assessed as heart rate at 10 uM perfused for 20 mins (Rvb = -3 +/- 3%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076374Drug uptake into Sprague-Dawley rat hepatocytes by silicone oil layer method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076378Drug uptake in Beagle dog liver at 14 mg/kg, po after 24 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076380Oral bioavailability in Beagle dog by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434259AUC in id dosed rat plasma after 4 hrs2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID759174Solubility of the compound at pH 7.22013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
AID1323429Cardiotoxicity in rabbit heart assessed as change in sinoatrial node recovery time at 10 uM perfused for 20 mins measured for 1 min by electrophysiology method relative to control2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323418Drug uptake in cannulated Sprague-Dawley rat liver at 15 mg/kg administered via oral gavage measured at 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1076369Mutagenicity in Salmonella typhimurium by Ames test2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076389Oral bioavailability in Sprague-Dawley rat at 15 mg/kg administered via gavage by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1323409Antiviral activity against HCV genotype 1b Con1 expressing NS3 protease infected in human Huh7.5 cells assessed as reduction in viral RNA replication by luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1076370Inhibition of CYP3A4 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076391Drug uptake in intraduodenally dosed Sprague-Dawley rat liver measured per gm of tissue over 4 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434256Antiviral activity against HCV genotype 1b by cell based replicon assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1323410Inhibition of HCV genotype 1a NS3 protease using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323417AUC in cannulated Sprague-Dawley rat plasma at 15 mg/kg administered via oral gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1434266Cardiotoxicity in Langendorff perfused rabbit heart assessed as heart rate at 10 uM perfused for 10 mins (Rvb = -1 +/- 1%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076382Antiviral activity against Canine parainfluenza virus2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434270Cardiotoxicity in Langendorff perfused rabbit heart assessed as coronary flow at 10 uM perfused for 10 mins (Rvb = -4 +/- 6%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID759187Inhibition of Hepatitis C virus NS3 protease2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
AID1434268Cardiotoxicity in Langendorff perfused rabbit heart assessed as sinoatrial node recovery time at 10 uM perfused for 10 mins (Rvb = 3 +/- 1%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076377Plasma concentration in Beagle dog at 14 mg/kg, po after 24 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076381Antiviral activity against Human immunodeficiency virus2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076371Binding affinity to P-glycoprotein (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434263Clearance in rat at 5 mg/kg, iv2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076360Cardiovascular toxicity in Hepatitis C virus genotype 1 infected human assessed as PR-interval prolongation at 120 mg, po by electrocardiography2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434262AUC in rat at 15 mg/kg, po after 24 hrs2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076365Antiviral activity against Hepatitis C virus genotype 1 infected in human assessed as reduction in plasma viral load at 120 mg, po after 12 hrs2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076358Antiviral activity against Hepatitis C virus genotype 1a H77 assessed as inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 4 days by cell-based HCV replicon assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076379Oral bioavailability in cynomolgus monkey at 3 mg/kg administered via gavage by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434260Drug uptake in id dosed rat liver after 4 hrs2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076387Drug uptake in Sprague-Dawley rat liver at 15 mg/kg, po administered via gavage measured after 24 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076363Cardiovascular toxicity in healthy human assessed as PR-interval prolongation at 120 mg, po by electrocardiography2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1392004Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1076367Terminal half life in po dosed human2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1434257Permeability of the compound at pH 5.5 by PAMPA2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076359Cardiovascular toxicity in Hepatitis C virus genotype 1 infected human assessed as junctional rhythm disturbances at 120 mg, po by electrocardiography2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076398Half life in rat liver microsomes at 3 uM by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076373Drug uptake into dog hepatocytes by silicone oil layer method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID759188Antiviral activity against Hepatitis C virus2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
AID1076388Cytotoxicity against human HuH7 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1323416Oral bioavailability in cannulated Sprague-Dawley rat plasma at 15 mg/kg administered via gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1392007Drug level in Sprague-Dawley rat liver at 15 mg/kg administered intraduodenally as single dose measured at 4 hrs by LC/MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1434261Oral bioavailability in rat at 15 mg/kg after 24 hrs2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076357Genotoxicity in micronucleus (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1076384Selectivity for HCV NS3/4A protease over GBV-B NS3 protease2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1323411Half life in human liver microsomes2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1392006AUC in Sprague-Dawley rat plasma at 15 mg/kg administered intraduodenally as single dose measured at 4 hrs by LC/MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1434269Cardiotoxicity in Langendorff perfused rabbit heart assessed as sinoatrial node recovery time at 10 uM perfused for 20 mins (Rvb = 4 +/- 5%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1434271Cardiotoxicity in Langendorff perfused rabbit heart assessed as coronary flow at 10 uM perfused for 20 mins (Rvb = -6 +/- 8%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1076385Plasma concentration in Sprague-Dawley rat at 15 mg/kg, po administered via gavage measured after 24 hrs by LC/MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID1392002Antiviral activity against HCV genotype 1b infected in human Huh7.5 replicon cells assessed as reduction in viral replication incubated for 4 days by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1323414Half life in cannulated Sprague-Dawley rat plasma at 5 mg/kg, iv administered as 10 mins infusion by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1076364Cardiovascular toxicity in healthy human assessed as mild bradycardia at 120 mg, po by electrocardiography2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bms-650032
asunaprevir: an NS3 protease inhibitor against hepatitis C virus		2.8430oligopeptide
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		02.5220
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		07.5220
Chronic Hepatitis C
[description not available]		02.0810
Hepatitis C, Chronic
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.		02.0810